IV Brincidofovir is a novel antiviral medication being developed by SymBio Pharmaceuticals for the treatment of various viral infections, including adenovirus infection following hematopoietic stem cell transplantation and Epstein-Barr virus associated lymphoproliferative disease. It is currently in clinical trials.